TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/21/24 15:07 | 11/21/24 | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | M.d | 20 | 1.55 | 0 | 13 | 4 | 344 | D | ||||||||||||||
7/19/24 08:29 | 7/17/24 | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -146 | 6.47 | 0 | -23 | -6 | 331 | D | ||||||||||||||
7/15/24 08:35 | 7/11/24 | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | S | -121 | 5.97 | 0 | -20 | -5 | 353 | D | ||||||||||||||
12/12/22 16:25 | 12/8/22 | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | P.m | 30 | 1.88 | 0 | 16 | 64 | 41 | D | ||||||||||||||
8/2/21 20:09 | 7/29/21 | CADL | Candel Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Tak Paul Peter | MA | DO | CEO | P | 200 | 8.00 | 0 | 25 | New | 25 | D |
D | Derivative transaction in filing (usually option exercise) |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
A | Amended filing |
E | Error detected in filing |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |